Explore the landscape of obesity medication in Canada as we delve into the studies behind Ozempic, Wegovy, Mounjaro, Contrave, Saxenda, and Orlistat. Wegovy, Saxenda, Contrave and Orlistat are the only drugs currently (March 2024) approved for the treatment of obesity, while Ozempic and Mounjaro are approved for the treatment of type 2 diabetes.

We'll discuss their efficacy, adverse effects, costs, and availability, along with pertinent social issues. Please note, this video is not medical advice; it's intended for the BPK 417 class on obesity and weight management.